1095274-85-3

Upstream product

• 598-39-0 1,1-difluoro-2-iodoethane 
• 1095274-84-2 ethyl 3-chloro-5-(3-pyrrolidinyl)benzoate 
• 42860-02-6 3‐bromo‐5‐chlorobenzoic acid 
• 1095274-82-0 ethyl 3-chloro-5-[3-(ethyloxy)-1-(nitromethyl)-3-oxopropyl]benzoate 
• 1095274-81-9 ethyl 3-chloro-5-[(1E)-3-(ethyloxy)-3-oxo-1-propen-1-yl]benzoate 
• 1095274-83-1 ethyl 3-chloro-5-(5-oxo-3-pyrrolidinyl)benzoate 
• 1095274-55-7 3-bromo-5-chlorobenzoic acid ethyl ester 
• 1168106-86-2 ethyl [4-[3-amino-1-azetidinyl]-5-(2-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetate 

Relevant academic research and scientific papers

3-OXO-2, 3-DIHYDRO- [1,2, 4] TRIAZOLO [4, 3-A]PYRIDINES AS SOLUBLE EPOXIDE HYDROLASE (SEH) INHIBITORS

Claimed are intermediates in the synthesis of N-Arylmethyl-3-Oxo-2,3-dihydro- [1,2,4]triazolo[4,3-a]pyridine-6-carboxamides as well as a process (A) to arrive at 3-Oxo-2, 3-dihydro-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid. The triazolo[4,3-a]pyridine-6-carboxamides of formula (I) are used as soluble epoxide hydrolase inhibitors (sEH) having therapeutic effect in pathologic conditions such as hypertension, stroke, inflammatory processes, diabetes and a variety of cardiovascular diseases.

5-PHENYL-1,3,4-OXADIAZOL-2-YL-ACETYL-4-PIPERIDINYL DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The present invention relates to novel compounds that are CGRP receptor antagonists, processes for their preparation, to compositions containing them and to their use in the treatment of migraine, headache, and cluster headache.